LLY

1,023.34

+1.71%↑

JNJ

230.48

+0.46%↑

ABBV

212.01

-0.57%↓

UNH

389.57

-0.81%↓

AZN

187.16

+1.18%↑

LLY

1,023.34

+1.71%↑

JNJ

230.48

+0.46%↑

ABBV

212.01

-0.57%↓

UNH

389.57

-0.81%↓

AZN

187.16

+1.18%↑

LLY

1,023.34

+1.71%↑

JNJ

230.48

+0.46%↑

ABBV

212.01

-0.57%↓

UNH

389.57

-0.81%↓

AZN

187.16

+1.18%↑

LLY

1,023.34

+1.71%↑

JNJ

230.48

+0.46%↑

ABBV

212.01

-0.57%↓

UNH

389.57

-0.81%↓

AZN

187.16

+1.18%↑

LLY

1,023.34

+1.71%↑

JNJ

230.48

+0.46%↑

ABBV

212.01

-0.57%↓

UNH

389.57

-0.81%↓

AZN

187.16

+1.18%↑

Kodu・Aktsiate loetelu・Fate Therapeutics Inc

Fate Therapeutics Inc

Avatud

SektorTervishoid

1.85 10.78

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.67

Max

1.9100000000000001

Põhinäitajad
By Trading Economics
Sissetulek	1.2M -31M
Müük	-70K 1.3M
Aktsiakasum	-0.26
Kasumimarginaal	-2,402.848
Töötajad	161
EBITDA	12M -30M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+153.76% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	10. aug 2026

Turustatistika
By TradingEconomics
Turukapital	-52M 202M
Eelmine avamishind	-8.93
Eelmine sulgemishind	1.85

Uudiste sentiment

By Acuity

46%

54%

157 / 345 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

0.9101 / 1.14 Toetus ja vastupanu

Fate Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

19. mai 2026, 20:36 UTC

Omandamised, ülevõtmised, äriostud

Analog Devices to Buy Empower Semiconductor for $1.5 Billion

19. mai 2026, 23:47 UTC

Market Talk

Nikkei May Decline as Concerns About Energy, Material Costs Persists -- Market Talk

19. mai 2026, 23:34 UTC

Market Talk

Gold Edges Higher on Possible Technical Recovery -- Market Talk

19. mai 2026, 23:28 UTC

Market Talk

Tulu

Global Forex and Fixed Income Roundup: Market Talk

19. mai 2026, 23:28 UTC

Market Talk

Tulu

F&P Healthcare's Outlook Key for Investors -- Market Talk

19. mai 2026, 23:10 UTC

Market Talk

Global Equities Roundup: Market Talk

19. mai 2026, 23:10 UTC

Market Talk

Kiwi Property's Dividend Growth Reliant on Several Factors -- Market Talk

19. mai 2026, 22:02 UTC

Tulu

ZTO Express (Cayman): Di Xu to Resign From Board

19. mai 2026, 22:01 UTC

Tulu

ZTO Express (Cayman) 1Q Adj EPS 43c >ZTO

19. mai 2026, 22:01 UTC

Tulu

ZTO Express (Cayman) 1Q EPS 39c >ZTO

19. mai 2026, 22:00 UTC

Tulu

ZTO Express (Cayman) 1Q Rev $1.93B >ZTO

19. mai 2026, 21:37 UTC

Tulu

Cracks Are Starting to Appear in the Chip Stock Rally -- Barrons.com

19. mai 2026, 21:31 UTC

Omandamised, ülevõtmised, äriostud

How NextEra Can Fix Dominion's Strange AI Problem -- Barrons.com

19. mai 2026, 21:01 UTC

Tulu

Home Depot Beats Earnings Estimates as Shoppers Defy Inflation Fears. The Stock Advances. -- Barrons.com

19. mai 2026, 20:58 UTC

Tulu

These Stocks Are Today's Movers: CoreWeave, Nvidia, Home Depot, Akamai, Agilysys, Micron, and More -- Barrons.com

19. mai 2026, 20:46 UTC

Kuumad aktsiad

Stocks to Watch Recap: ServiceNow, Home Depot, CoreWeave -- WSJ

19. mai 2026, 20:43 UTC

Market Talk

Canada 30-Year Yield Hits Highest Level Since 2010 -- Market Talk

19. mai 2026, 20:34 UTC

Tulu

James Hardie Industries Sees FY27 Sales $5.25B-$5.41B >JHX

19. mai 2026, 20:32 UTC

Tulu

James Hardie Industries: Targeting Pro Forma Adjusted EBITDA Growth of 4% to 8% in FY27 >JHX

19. mai 2026, 20:32 UTC

Tulu

James Hardie Industries 4Q EPS 5c >JHX

19. mai 2026, 20:32 UTC

Tulu

James Hardie Industries 4Q Sales $1.4B >JHX

19. mai 2026, 20:21 UTC

Omandamised, ülevõtmised, äriostud

Analog Devices to Buy Empower Semiconductor for $1.5B

19. mai 2026, 20:18 UTC

Market Talk

Canada CPI Data Has Accounting Quirk Related to Travel Tours -- Market Talk

19. mai 2026, 20:13 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

19. mai 2026, 20:13 UTC

Market Talk

'Hard to Square' Canada Rate Hikes Expectations Given Mild Core -- Market Talk

19. mai 2026, 20:03 UTC

Omandamised, ülevõtmised, äriostud

Analog Devices: Deal Further Advances Position as Strategic, System-Level Grid-To-Core Power Partner for Hyperscalers, AI Silicon Developers >ADI

19. mai 2026, 20:03 UTC

Omandamised, ülevõtmised, äriostud

Analog Devices: Phillips Will Continue Leading IVR Technology Efforts as Part of ADI >ADI

19. mai 2026, 20:02 UTC

Omandamised, ülevõtmised, äriostud

Analog Devices Will Acquire Empower in All-Cash Transaction for $1.5 B >ADI

19. mai 2026, 20:02 UTC

Omandamised, ülevõtmised, äriostud

Analog Devices to Acquire Empower Semiconductor, Expanding Its Next-Generation High-Density Power Portfolio for the AI Era

19. mai 2026, 19:23 UTC

Market Talk

Oil Futures Slip With Market Back on U.S.-Iran Deal Watch -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Fate Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

153.76% tõus

12 kuu keskmine prognoos

Keskmine 4.39 USD 153.76%

Kõrge 7 USD

Madal 2 USD

Põhineb 8 Wall Streeti analüütiku instrumendi Fate Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

8 ratings

Osta

Hoia

Müü

Põhineb 8 analüütiku instrumendi Fate Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

0.9101 / 1.14Toetus ja vastupanu

Recent bearish events outweigh bullish events.

All events are bullish.

There are no events.

Sentiment

By Acuity

157 / 345 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.